Nikolay Zhurilo
Overview
Explore the profile of Nikolay Zhurilo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
23
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lukin A, Bakholdina A, Zhurilo N, Onopchenko O, Zhuravel E, Zozulya S, et al.
Arch Pharm (Weinheim)
. 2020 Dec;
354(4):e2000275.
PMID: 33270252
Three types of heterocyclic moieties-piperidines fused to a heteroaromatic moiety-were explored as potential periphery motifs for the pharmacophoric core of fasiglifam (TAK-875), with fasiglifam being the most advanced agonist of...
2.
Lukin A, Kramer J, Hartmann M, Weizel L, Hernandez-Olmos V, Falahati K, et al.
Bioorg Chem
. 2018 Jul;
80:655-667.
PMID: 30059891
Spirocyclic 1-oxa-9-azaspiro[5.5]undecan-4-amine scaffold was explored as a basis for the design of potential inhibitors of soluble epoxide hydrolase (sEH). Synthesis and testing of the initial SAR-probing library followed by biochemical...
3.
Krasavin M, Lukin A, Bakholdina A, Zhurilo N, Onopchenko O, Borysko P, et al.
Eur J Med Chem
. 2017 Sep;
140:229-238.
PMID: 28938138
An earlier reported series of 1,2,4-thiadiazole-based agonists of FFA1 (GPR40) was evolved into two structurally distinct series of compounds. One of the series (structurally related to known FFA1 agonist GW9508)...
4.
Krasavin M, Lukin A, Bagnyukova D, Zhurilo N, Golovanov A, Zozulya S, et al.
Eur J Med Chem
. 2017 Jan;
127:357-368.
PMID: 28076825
A series of spirocyclic compounds inspired by Eli Lilly's phase 1 antidiabetic FFA1 receptor agonist LY2881835 was designed to include polar aromatic periphery groups and explore a possibility of building...
5.
Krasavin M, Lukin A, Bagnyukova D, Zhurilo N, Zahanich I, Zozulya S
J Enzyme Inhib Med Chem
. 2016 Oct;
32(1):29-36.
PMID: 27781494
A series of nine compounds based on 3-[4-(benzyloxy)phenyl]propanoic acid core containing a 1-oxa-9-azaspiro[5.5]undecane periphery was designed, synthesized and evaluated as free fatty acid 1 (FFA1 or GPR40) agonists. The spirocyclic...
6.
Krasavin M, Lukin A, Bagnyukova D, Zhurilo N, Zahanich I, Zozulya S, et al.
Bioorg Med Chem
. 2016 Sep;
24(21):5481-5494.
PMID: 27647366
The free fatty acid receptor 1 (FFA1), a G protein-coupled receptor (GPCR) naturally activated by long-chain fatty acids is a novel target for the treatment of metabolic diseases. The basic...
7.
Krasavin M, Lukin A, Zhurilo N, Kovalenko A, Zahanich I, Zozulya S, et al.
Bioorg Med Chem
. 2016 May;
24(13):2954-2963.
PMID: 27229618
Free fatty acid receptor 1 (FFA1), previously known as GPR40 is a G protein-coupled receptor and a new target for treatment of type 2 diabetes. Two series of FFA1 agonists...
8.
Krasavin M, Lukin A, Zhurilo N, Kovalenko A, Zahanich I, Zozulya S
J Enzyme Inhib Med Chem
. 2016 Feb;
31(6):1404-10.
PMID: 26899762
1,3,4-Thiadiazole was explored as a more polar, heterocyclic replacement for the phenyl ring in the 3-arylpropionic acid pharmacophore present in the majority of GPR40 agonists. Out of 13 compounds synthesized...